Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First US kidney cancer vaccine trial underway at Columbia

31.01.2005


Study of a Completely New Way of Trying to Treat Cancer in the Future by the Use of Vaccination Injections



The first U.S. kidney cancer vaccine trial is now underway at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia. While the potential for vaccines to treat solid tumors has been recognized for more than a decade, this trial is pioneering the use of tumor immunotherapy – boosting the body’s natural immune system – as a way to fight cancer.

“Vaccines are an exciting prospect in cancer treatment and this trial is an example of our program’s dedication to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer,” said Howard L. Kaufman, M.D., associate professor of surgery and pathology at Columbia University Medical Center and director, Tumor Immunotherapy Program at NewYork-Presbyterian/Columbia. “We expect that combining IL-2 with Trovax will double the treatment response rate for our kidney cancer patients, offering new hope for these patients.”


Vaccines, usually associated with the prevention of infectious diseases, e.g., measles, help the body’s immune system recognize and kill foreign invading organisms. Recent research has provided evidence that vaccines may also be useful for preventing or treating cancer. Tumor vaccines contain a specific protein of the tumor cell that stimulates an immune response.

In the study, patients with stage IV renal cell carcinoma are given regular doses of an investigational kidney cancer vaccine, called Trovax, in conjunction with Interleukin-2 (IL-2). High-dose IL-2 is currently the only approved treatment for kidney cancer, and Columbia University Medical Center and New York-Presbyterian Hospital/Columbia are the only site in New York to offer IL-2. Kidney cancer is one of the few cancers for which chemotherapies are not effective treatments.

A small protein (cytokine) naturally produced by the cells of the immune system, IL-2 stimulates T-cells, which are activated in an immune response system and create tumor killing cells. The response rate (i.e., rate of tumor shrinkage) of IL-2 given alone is typically 17-25 percent. While IL-2 stimulates all T-cells, the Trovax Vaccine helps IL-2 selectively target only cancer cells, reducing side effects by not targeting and unnecessarily killing normal cells. Trovax has shown promise in similar trials conducted in Europe in colon cancer.

About Trovax

Trovax belongs to a class of medicines called a vaccine. Trovax consists of a virus that has been changed so that it is no longer infectious and carries a gene for a protein called 5T4. This protein is carried by many kidney cancer calls. When the virus is injected, it makes the protein, and the body’s immune system is then able to recognize this protein and kill the cells that have it (i.e. the cancer cells).

About the Trial

The Trovax vaccine with IL-2 trial is being conducted by a team of physicians, scientists, nurses, pharmacists, and social workers with expertise in the use of immunotherapy in patients with cancer.

The trial aims to enroll 25 patients in total. To date, two patients have enrolled. Patients need to meet certain medical requirements to join the clinical trial. An interested patient or medical oncologist may contact us to learn about eligibility requirements. Participation is voluntary and patients may withdraw at any time.

For more information regarding participation in one of our trials, please contact Gail DeRaffele, RN, Clinical Coordinator at 212.342.0232 or gd2023@columbia.edu.

The Tumor Immunotherapy Program at NewYork-Presbyterian/Columbia, unique in the Metropolitan New York area, includes doctors and nurses with specialized training in biologic therapy and vaccines who are actively conducting clinical studies of tumor vaccines. The program also includes scientists working in research laboratories within Columbia University to translate clinical learnings into new vaccines and therapies.

Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, medical education, and health care. The medical center trains future leaders in health care and includes the dedicated work of many physicians, scientists, nurses, dentists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. With a strong history of some of the most important advances and discoveries in health care, its researchers are leading the development of novel therapies and advances to address a wide range of health conditions.

New York-Presbyterian Hospital is the largest not-for-profit, non-sectarian hospital in the country. It provides state-of-the art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: New York-Presbyterian hospital/Columbia University Medical Center, New York-Presbyterian Hospital/Weill Cornell Medical Center, Children’s Hospital of New York-Presbyterian, the Allen Pavilion, and the Westchester Division. It consistently ranks as one of the top hospitals in the country in U.S. News & World Report’s guide to “America’s Best Hospitals.” The New York-Presbyterian Healthcare System – an affiliation of acute-care and community hospitals, long-term care facilities, ambulatory sites, and specialty institutes –serves one in four patients in the New York metropolitan area.

Elizabeth Streich | EurekAlert!
Further information:
http://www.columbia.edu

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

More genes are active in high-performance maize

19.01.2018 | Life Sciences

How plants see light

19.01.2018 | Life Sciences

Artificial agent designs quantum experiments

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>